PMDA drug package insert
フォサマック錠35mg
PMDA Prescription drug · オルガノン株式会社 · package insert Jan 17, 2023
Key facts
| Brand names | フォサマック錠35mg |
|---|---|
| Nonproprietary names | アレンドロン酸ナトリウム水和物 |
| Companies | 製造販売元／オルガノン株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 骨粗鬆症治療薬 |
| Therapeutic category codes | 873999 |
| YJ codes | 3999018F2028 |
| Approval numbers | 21800AMZ10364000 |
| Package insert edition | 第4版 |
| Package insert date | Jan 17, 2023 |
| PMDA document key | 181615_3999018F2028_3 |
| PMDA company code | 181615 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: